EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pyxis Oncology's Enterprise Value is $149.31 Mil.
Pyxis Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-77.44 Mil. Therefore, Pyxis Oncology's EV-to-FCF for today is -1.93.
The historical rank and industry rank for Pyxis Oncology's EV-to-FCF or its related term are showing as below:
PYXS'
s EV-to-FCF Range Over the Past 10 Years
Min: -26.34 Med: 0 Max: 5.23
Current: -1.93
During the past 5 years, the highest EV-to-FCF of Pyxis Oncology was 5.23. The lowest was -26.34. And the median was 0.00.
PYXS's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.56
vs PYXS: -1.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Pyxis Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's EV-to-FCF
For the Biotechnology subindustry, Pyxis Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EV-to-FCF falls into.
Pyxis Oncology's current Enterprise Value is $149.31 Mil.
Pyxis Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-77.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (NAS:PYXS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pyxis Oncology's PE Ratio for today is calculated as:
Pyxis Oncology's share price for today is $4.21.
Pyxis Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.840.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pyxis Oncology EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 